Zycan is a Disease Modifying Osteoarthritis Drug (DMOAD) for the treatment and prevention of clinical signs attributable
to degenerative and/or traumatic aseptic joint disease in horses. DMOADs are intended to prevent, retard or reverse the
morphologic cartilaginous lesions associated with degenerative joint disease (DJD).
PSGAGs, such as Zycan have been advocated for the (i) preventative treatment of joint disease (ii) chronic joint maintenance
programs and (iii) post-operative care of horses returning to training following joint surgery.
There are no reviews yet.